A multidimensional platform of patient-derived tumors identifies drug susceptibilities for clinical lenvatinib resistance

• Egile Nagusiak: Lei Sun (Egilea), Arabella H. Wan (Egilea), Shijia Yan (Egilea), Ruonian Liu (Egilea), Jiarui Li (Egilea), Zhuolong Zhou (Egilea), Ruirui Wu (Egilea), Dongshi Chen (Egilea), Xianzhang Bu (Egilea), Jingxing Ou (Egilea), Kai Li (Egilea), Xiongbin Lu (Egilea), Guohui Wan (Egilea), Zunfu Ke (Egilea)
• Formatua: Liburua
• Argitaratua: Elsevier, 2024-01-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Lenvatinib, a second-generation multi-receptor tyrosine kinase inhibitor approved by the FDA for first-line treatment of advanced liver cancer, facing limitations due to drug resistance. Here, we applied a multidimensional, high-throughput screening platform comprising patient-derived resistant live...